Literature DB >> 10064674

Etidronate therapy for hypercalcemia in subcutaneous fat necrosis of the newborn.

A M Rice1, S A Rivkees.   

Abstract

Subcutaneous fat necrosis of the newborn (SCFN) is characterized by indurated violet skin nodules and, occasionally, life-threatening hypercalcemia. Current treatments of patients with SCFN-related hypercalcemia are often only partially successful and may be associated with prolonged hypercalcemia. We now report the use of etidronate, a bisphosphonate, to control hypercalcemia in an infant with SCFN.

Entities:  

Mesh：

Substances：

Year:  1999        PMID： 10064674     DOI： 10.1016/s0022-3476(99)70462-2

Source DB:  PubMed          Journal:  J Pediatr        ISSN： 0022-3476            Impact factor:   4.406


  10 in total

1.  A 1-week-old newborn with hypercalcemia and palpable nodules: subcutaneous fat necrosis.

Authors:  Fahed Aljaser; Michael Weinstein
Journal:  CMAJ       Date:  2008-06-17       Impact factor: 8.262

2.  Alendronate for the treatment of hypercalcaemia due to neonatal subcutaneous fat necrosis.

Authors:  Nilay Hakan; Mustafa Aydin; Ayşegul Zenciroglu; Nihal Demirel; Nurullah Okumus; Semra Cetinkaya; Mehmet Sah Ipek
Journal:  Eur J Pediatr       Date:  2011-04-13       Impact factor: 3.183

Review 3.  Bisphosphonate treatment of bone disease.

Authors:  N J Shaw; N J Bishop
Journal:  Arch Dis Child       Date:  2005-05       Impact factor: 3.791

4.  Pamidronate treatment of pediatric fracture patients on chronic steroid therapy.

Authors:  Philip D Acott; Jaime A Wong; Bianca A Lang; John F S Crocker
Journal:  Pediatr Nephrol       Date:  2005-02-03       Impact factor: 3.714

5.  Expression of 25-hydroxyvitamin D3-1alpha-hydroxylase in subcutaneous fat necrosis.

Authors:  A Farooque; C Moss; D Zehnder; M Hewison; N J Shaw
Journal:  Br J Dermatol       Date:  2008-09-20       Impact factor: 9.302

6.  Severe neonatal hypercalcemia caused by subcutaneous fat necrosis without any apparent cutaneous lesion.

Authors:  Laurent Bonnemains; Stephanie Rouleau; Gaelle Sing; Claude Bouderlique; Regis Coutant
Journal:  Eur J Pediatr       Date:  2008-03-26       Impact factor: 3.183

7.  Treatment with bisphosphonates in severe hypercalcemia due to subcutaneous fat necrosis in an infant with hypoxic-ischemic encephalopathy.

Authors:  E Pérez Martínez; M Camprubí Camprubí; M Ramos Cebrián; J Antón López; A Apodaca Saracho; M G Lopez Ramos; A García-Alix
Journal:  J Perinatol       Date:  2014-06       Impact factor: 2.521

Review 8.  The role of bisphosphonates in diseases of childhood.

Authors:  Tarak Srivastava; Uri S Alon
Journal:  Eur J Pediatr       Date:  2003-09-11       Impact factor: 3.183

9.  Pamidronate as first-line treatment of hypercalcemia in neonatal subcutaneous fat necrosis: A case series.

Authors:  Alexander D Chesover; Jennifer Harrington; Farid H Mahmud
Journal:  Paediatr Child Health       Date:  2019-12-24       Impact factor: 2.253

10.  Extensive subcutaneous fat necrosis complicated by neonatal hypercalcaemia.

Authors:  Waad M Al-Ghamdi; Asmaa Adel Milyani; Abdulmoein Eid Al-Agha
Journal:  Acta Biomed       Date:  2021-04-30
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.